comparemela.com

Latest Breaking News On - Warfighter medical research program - Page 2 : comparemela.com

I3R Neural Prosthesis Project Gets $5M Grant From Defense Department

The grant will add Walter Reed National Military Medical Center in Bethesda, Maryland, as a second clinical trial site.

United statesWalter reedPaul pasquinaErika petersenDrug administrationWalter reed national military medical centerWarfighter medical research programWalter reed national medical centerUs department of defenseUniformed services universityArkansa instituteInnovative researchHuman researchJoint warfighter medical research

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific.

United statesFrance generalPierre kymeDeborah birxDeborahl birxJoyce allairePrnewswire armata pharmaceuticals incArmata pharmaceuticals incDefense health agencyTechnology enterprise consortiumWarfighter medical research programUs department of defenseLifesci advisorsRecent developmentsInnoviva boardChief executive

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific.

United statesPierre kymeJoyce allaireBrian varnumArmata pharmaceuticals incDefense health agencyInnoviva incTechnology enterprise consortiumPrnewswire armata pharmaceuticals incInnoviva strategic opportunitiesUs department of defenseLifesci advisorsWarfighter medical research programRecent developmentsChief executive officerMedical technology enterprise consortium

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific.

United statesBrian varnumJoyce allairePierre kymeUs department of defenseLifesci advisorsDefense health agencyArmata pharmaceuticals incWarfighter medical research programInnoviva incInnoviva strategic opportunitiesTechnology enterprise consortiumPrnewswire armata pharmaceuticals incRecent developmentsChief executive officerMedical technology enterprise consortium

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific.

United statesBrian varnumJoyce allairePierre kymeUs department of defenseLifesci advisorsDefense health agencyArmata pharmaceuticals incWarfighter medical research programTechnology enterprise consortiumPrnewswire armata pharmaceuticals incRecent developmentsChief executive officerMedical technology enterprise consortiumJoint warfighter medical researchArmata pharmaceuticals

vimarsana © 2020. All Rights Reserved.